Efficacy of Ayurvedic Medication on Anxiety-induced Migraine: A Case Study

Preeti Bhatt; D.B. Vaghela

doi:10.21760/jaims.9.9.45

Preeti Bhatt Post Graduate Scholar Final Year, Dept. of Shalakya Tantra, Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India.
D.B. Vaghela Head & Professor, Dept. of Shalakya Tantra, Institute of Teaching and Research in Ayurveda, Jamnagar, Gujarat, India.

DOI: https://doi.org/10.21760/jaims.9.9.45

Keywords: Anxiety-induced Migraine, Laghu Sutashekhara Rasa, Brihata Dashmoola Taila, Tablet Anzee, Rasayana Yoga

Abstract

Anxiety-induced Migraine is a complex and debilitating condition where physiological and psychological stress trigger severe headache episodes. Throbbing pain which is typical of Migraine headache presented with distressing symptoms of anxiety, significantly impacts the quality of life for sufferers. The relationship between stress and Migraine is bidirectional; not only can anxiety provoke Migraine, but the chronic pain and disruption caused by Migraine can also heighten anxiety levels, creating a vicious cycle. In Ayurveda, Ardhavabhedaka is mentioned with the characterization of headache in half of the head (hemicrania) which is the main feature of Migraine. A 29-year-old man with complaints of headache visited Shalakya Tantra OPD of the Institute of Teaching and Research in Ayurveda, Jamnagar for his Anxiety-induced Migraine. He was treated with Laghu Sutashekhara Rasa, Brihata Dashmoola Taila Nasya, Tablet Anzee (combination of Tagar, Ashwagandha, Brahmi, and Sankhapusphi) and Rasayana Yoga. There was a significant improvement in all three parameters of duration, severity, and frequency of headache and the most important was a reduction in frequency of headaches. The combination of medications shows improvement in the signs and symptoms of Migraine with Anxiety. This study recommends the importance of clinical protocol and evaluation with the clinical study for evaluating efficacy and safety.

Downloads

Download data is not yet available.

References

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:12018; 38:1–211. https://doi.org/10.1177/ 0333102417738202.

Uzun S, Frejvall U, Özkaya-Sahin G, Sahin G. A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy? Front Neurol 2023;14. https://doi.org/10.3389/fneur.2023.1176816.

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:3432007; 68:343–9. https://doi.org/10.1212/ 01.wnl.0000252808.97649.21.

Migraine. Available from: http://www.namstp.ayush. gov.in

Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 2022;23. https://doi.org/10.1186/s10194-022-01431-x.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med 2017;377:21132017; 377:2113–22. https://doi.org/ 10.1056/nejmoa1709038.

Tabrecta. Available from https://www.webmd.com /drugs/2/drug-179310/tabrecta-oral/details

Nitrofurantoin. Available from https://www.drugs.com /nitrofurantoin.html

Proptric. Available from https://www.practo.com/ medicine-info/cita-s-10-mg-tablet-17179

Trøstheim M, Eikemo M, Meir R, Hansen I, Paul E, Kroll SL, et al. Assessment of Anhedonia in Adults Withwith and Without Mental Illness. JAMA Netw Open 2020;3:e2013233. https://doi.org/10.1001/ jamanetworkopen.2020.13233.

Mihaiu J, Bodog F, Mohan A, Vieriu G, et al. Successful management of chronic migraine through manual therapy. A case report. JMedLife 2023;16:9532023; 16:953–6. https://doi.org/10.25122/jml-2023-0222.